In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $127.00. The company’s shares closed yesterday at $75.94.
Timashev covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Edgewise Therapeutics, and Biohaven Ltd.. According to TipRanks, Timashev has an average return of 18.4% and a 39.58% success rate on recommended stocks.
In addition to RBC Capital, Axsome Therapeutics also received a Buy from Truist Financial’s Joon Lee in a report issued today. However, yesterday, Bank of America Securities reiterated a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).
AXSM market cap is currently $3.61B and has a P/E ratio of -14.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics (AXSM) Company Description:
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics announces anticipated milestones
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- Axsome Therapeutics reports Q1 EPS ($1.44), consensus ($1.20)
- AXSM Earnings this Week: How Will it Perform?
